罗沙司他与大剂量rHuEPO治疗腹膜透析肾性贫血患者的效果及安全性  

Efficacy and Safety of Roxadustat and High-dose rHuEPO in the Treatment of Peritoneal Dialysis Patients with Renal Anemia

作　　者：刘玉 王稻[1] 曹珊[1] 陈清萍[1] 廖雯[1] LIU Yu;WANG Dao;CAO Shan;CHEN Qingping;LIAO Wen(Department of Nephrology,Pingxiang People's Hospital,Pingxiang 337000,China;不详)

机构地区：[1]萍乡市人民医院肾病科,江西萍乡337000

出　　处：《中国医学创新》2024年第12期14-17,共4页Medical Innovation of China

摘　　要：目的:探讨罗沙司他与大剂量重组人促红素(rHuEPO)治疗腹膜透析肾性贫血患者的效果及安全性。方法:选择萍乡市人民医院2022年7—12月收治的60例腹膜透析肾性贫血患者进行本次研究,按照随机数字表法分为两组,各30例。对照组采用大剂量rHuEPO治疗,研究组采用大剂量rHuEPO联合罗沙司他治疗。对比两组疗效和治疗前后肾功能指标[血尿素氮(BUN)、血肌酐(Scr)、β_(2)-微球蛋白(β_(2)-MG)]、血液营养指标[血红蛋白(Hb)、红细胞压积(HCT)、红细胞(RBC)计数]、甲状旁腺激素(PTH)、铁代谢指标[血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)]及不良反应。结果:治疗后,研究组总有效率为90.00%,显著高于对照组的63.33%,差异有统计学意义(P<0.05);治疗后,研究组Hb、HCT、RBC均显著高于对照组,PTH显著低于对照组,差异均有统计学意义(P<0.05);治疗后,研究组SF、TSAT均显著高于对照组(P<0.05);治疗后,研究组BUN、Scr、β_(2)-MG均显著低于对照组,差异均有统计学意义(P<0.05)。结论:罗沙司他联合大剂量rHuEPO治疗可有效改善腹膜透析肾性贫血患者的贫血情况,纠正铁代谢,且不良反应少。Objective:To investigate the efficacy and safety of Roxadustat and high-dose Recombinant Human Erythropoietin(rHuEPO)in the treatment of peritoneal dialysis patients with renal anemia.Method:A total of 60 peritoneal dialysis patients with renal anemia admitted to Pingxiang People's Hospital from July to December 2022 were selected for this study.They were divided into two groups according to random number table method,with 30 cases in each group.The control group was treated with high-dose rHuEPO,and the study group was treated with high-dose rHuEPO combined with Roxadustat.The therapeutic effect and renal function indexes[blood urea nitrogen(BUN),serum creatinine(Scr),β_(2)-microglobulin(β_(2)-MG)],blood nutrition indexes[hemoglobin(Hb),hematocrit(HCT),red blood cell(RBC)count],parathyroid hormone(PTH),iron metabolism indexes[serum ferritin(SF),transferrin saturation(TSAT)]before and after treatment and adverse reactions were compared between the two groups.Result:After treatment,the total effective rate of the study group was 90.00%,which was significantly higher than 63.33% of the control group,the difference was statistically significant(P<0.05).After treatment,Hb,HCT and RBC in the study group were significantly higher than those in the control group,and PTH was significantly lower than that in the control group,the differences were statistically significant(P<0.05).After treatment,SF and TSAT in the study group were significantly higher than those in the control group(P<0.05).After treatment,BUN,Scr andβ_(2)-MG in the study group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Roxadustat combined with high-dose rHuEPO can effectively improve the anemia of peritoneal dialysis patients with renal anemia,correct iron metabolism,and have few adverse reactions.

关 键 词：腹膜透析 肾性贫血 罗沙司他 重组人促红素 安全性 

分 类 号：R692.5[医药卫生—泌尿科学]